- Home
- CNF vs MIST Comparison
CNF vs MIST Comparison
Compare CNF & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNF
- MIST
- Stock Information
- Founded
- CNF 1999
- MIST 2003
- Country
- CNF China
- MIST Canada
- Employees
- CNF N/A
- MIST N/A
- Industry
- CNF Finance: Consumer Services
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- CNF Finance
- MIST Health Care
- Exchange
- CNF Nasdaq
- MIST Nasdaq
- Market Cap
- CNF 35.7M
- MIST 89.8M
- IPO Year
- CNF 2018
- MIST N/A
- Fundamental
- Price
- CNF $0.80
- MIST $2.33
- Analyst Decision
- CNF
- MIST Strong Buy
- Analyst Count
- CNF 0
- MIST 2
- Target Price
- CNF N/A
- MIST $7.50
- AVG Volume (30 Days)
- CNF 274.3K
- MIST 640.4K
- Earning Date
- CNF 08-27-2025
- MIST 08-07-2025
- Dividend Yield
- CNF N/A
- MIST N/A
- EPS Growth
- CNF N/A
- MIST N/A
- EPS
- CNF 0.08
- MIST N/A
- Revenue
- CNF $85,661,735.00
- MIST N/A
- Revenue This Year
- CNF $252.34
- MIST N/A
- Revenue Next Year
- CNF N/A
- MIST N/A
- P/E Ratio
- CNF $9.68
- MIST N/A
- Revenue Growth
- CNF N/A
- MIST N/A
- 52 Week Low
- CNF $0.37
- MIST $0.63
- 52 Week High
- CNF $2.84
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- CNF 67.78
- MIST 78.63
- Support Level
- CNF $0.69
- MIST $1.86
- Resistance Level
- CNF $0.82
- MIST $1.97
- Average True Range (ATR)
- CNF 0.08
- MIST 0.12
- MACD
- CNF 0.03
- MIST 0.04
- Stochastic Oscillator
- CNF 93.55
- MIST 97.12
About CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).